Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe - Biophytis (NASDAQ:BPTS)

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA ((Nasdaq CM:BPTS, PARIS:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics

Related Keywords

Veillet ,Rhôalpes ,France ,Belgium ,Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Massachusetts ,Paris ,France General ,Belgian ,Nicolas Fellmann ,Nizar Berrada ,Antoine Denry ,European Medicine Agency ,Drug Administration ,Exchange Commission ,Ethics Committee ,Chief Executive Officer ,Emergency Use Authorization ,Duchenne Muscular Dystrophy ,Euronext Growth ,American Depositary Shares ,Nasdaq Capital Market ,